期刊
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
卷 44, 期 3, 页码 173-183出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.109.068312
关键词
probes; new technologies; breast cancer; collaboration
资金
- Ontario Institute of Cancer Research (OICR)
- Cancer Care Ontario (CCO)
- Ontario Research Fund (ORF)
- Canadian Institutes of Health Research (CIHR)
- Natural Sciences and Engineering Research Council (NSERC)
- Molecular Insight Pharmaceuticals (MIP)
- Biotage Inc.
- Pfizer Inc.
- federal government's Centers of Excellence for Commercialization and Research (CECR) program
- Cancer Care Ontario
- Ontario Institute for Cancer Research
- Ontario Ministry of Research and Innovation
The field of nuclear medicine will rely increasingly on the discovery, proper evaluation, and clinical use of molecular imaging probes and on collaborations. Collaborations will include new initiatives among experts already involved in the field and with researchers, technologists, and clinicians from different areas of science and medicine. This article serves to highlight some of the opportunities in which molecular imaging and nuclear medicine in conjunction with probe development, new imaging technologies, and multidisciplinary collaborations can have a significant impact on health care and basic science from the perspective of a person involved in probe development. The article emphasizes breast cancer, but the concepts are readily applied to other areas of medicine and medical research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据